ABSTRACT
This chapter presents the case of Pyrosequencing. It focuses on the innovation and development of a new and innovative technology for sequencing and analysing DNA, intended for scientific and commercial use. The chapter follows the development process in four phases. The first phase begins in 1986 when one of the founders, Pål Nyrén, at the time a young researcher, came up with a new idea for sequencing human DNA. This phase ends with the formation of a commercial company built around this innovation, called Pyrosequencing AB, aiming to get as large market share as possible of sequencing market. The second phase recounts how a venture capital firm, called HealthCap, became a main owner of Pyrosequencing AB. The third phase recounts how Pyrosequencing became a listed company on the stock exchange. In the final phase, the company's profit and loss statement is in focus as well as company's cash reserve that in end led to a revered initial public offering (IPO).
